Aratana Therapeutics Inc

Most Recent

  • uploads///Chart
    Earnings Report

    Analyzing Eli Lilly’s Clinical and Business Developments in 1Q16

    Elanco, the animal healthcare arm of Eli Lilly, received exclusive and global rights to develop and commercialize Aratana’s (PETX) Gallipart, a drug that treats osteoarthritis in dogs.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s Top Performers: PETX Gains on Its First FDA Approval

    IBB’s top performers for March 21, 2016, were Cara Therapeutics (CARA), OvaScience (OVAS), Sarepta Therapeutics (SRPT), and Aratana Therapeutics (PETX).

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Begins the Last Week of 2015 on a Negative Note

    The iShares Nasdaq Biotechnology ETF (IBB) fell by 0.75% on December 28, underperforming the broader market.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.